Acquisitions and Divestitures - Consideration Paid For HRA Pharma (Details) $ in Millions, € in Billions	Apr. 29, 2022 EUR (€)	Apr. 29, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Assets acquired:
Goodwill			$ 3,490.4	$ 2,999.4	$ 3,095.7
HRA Pharma
Business Acquisition [Line Items]
Purchase Price	€ 1.8	$ 1,945.6
Assets acquired:
Cash and cash equivalents		44.2
Accounts receivable		78.1
Inventories		48.3
Prepaid expenses and other current assets		16.6
Property, plant and equipment, net		4.6
Operating lease assets		9.7
Goodwill		559.5
Indefinite-lived intangibles: (1)		1,446.2
Deferred income taxes		12.4
Other non-current assets		0.8
Total assets		2,220.4
Liabilities assumed:
Accounts payable		43.4
Deferred income taxes		16.1
Accrued customer programs		9.0
Other accrued liabilities		8.9
Accrued income taxes		0.5
Deferred income taxes		186.2
Other non-current liabilities		10.6
Total liabilities		274.7
Noncontrolling interest		0.1
Net assets acquired		1,945.6
HRA Pharma | In-process research and development
Assets acquired:
Indefinite-lived intangibles: (1)		52.7
HRA Pharma | Trademarks and trade names
Assets acquired:
Definite-lived intangibles:		1,124.0
HRA Pharma | Developed product technology
Assets acquired:
Definite-lived intangibles:		185.1
HRA Pharma | Distribution networks
Assets acquired:
Definite-lived intangibles:		$ 84.4